Advertisement

Topics

Shionogi & Co., Ltd. Company Profile

12:01 EST 18th December 2018 | BioPortfolio

Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi’s Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain and Metabolic Syndrome. The Company has provided such innovative medicines as Crestor and Doripenem, which have been successfully delivered to millions of patients. In addition, Shionogi is engaged in new research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi’s primary goal. For more details, please visit www.shionogi.co.jp. For more information on Shionogi Inc., headquartered in Florham Park, NJ, please visit www.shionogi.com.


News Articles [80 Associated News Articles listed on BioPortfolio]

Shionogi Announces U.S. Availability of Mulpleta® (Lusutrombopag) for the Treatment of ...

Corporate Communications, Shionogi & Co., Ltd.Telephone: +81-6-6209-7885orShionogi Inc. U.S. MediaLindsay Bohlander, +1 973-307-3718Directorlindsay.bohlander@shionogi.com Read m...

Shionogi's influenza drug gets FDA nod

Shionogi's priority review-tagged orally administered Xofluza, or baloxavir marboxil, was approved by the FDA to treat patien -More- 

Shionogi's lusutrombopag, naldemedine gain positive opinion from CHMP

The European Medicines Agency's Committee for Medicinal Products for Human Use has backed the approval of two of Shionogi's m -More- 

Shionogi Announces U.S. Availability of Mulpleta

NewsMulpleta is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.

FDA approves Shionogi’s Mulpleta for CLD-associated thrombocytopenia

The US Food and Drug Administration (FDA) has approved Japanese pharmaceutical company Shionogi’s drug Mulpleta (lusutrombopag) indicated for thrombocytopenia in...Read More... The post FDA approves...

Sage and Shionogi to advance depression drug in Asia

US-based biopharmaceutical Sage Therapeutics has partnered with Japanese pharmaceutical firm Shionogi over clinical development and commercialisation of its drug candidate,...Read More... The post Sag...

Shionogi Regains Full Rights To Symproic In U.S.

NewsShionogi has begun its own sales and distribution of Symproic, and is in the process of seeking a new partner with strong commercial capabilities.Contributed Author:&

FDA Approves Shionogi’s Mulpleta

Shionogi, based in Osaka, Japan and Florham Park, New Jersey, announced that the U.S. Food and Drug Administration (FDA) approved Mulpleta (lusutrombopag) for thrombocytopenia in adults with chronic l...

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]

Prenate elite [Shionogi Pharma, Inc.]

PRENATE ELITE Tablets Rx

Prenate essential [Sciele Pharma, Inc.]

Prenate Essential™ Rx prenatal vitamin & DHA

Robinul [Shionogi Pharma, Inc.]

Robinul and Robinul Forte

Cedax [Sciele Pharma, Inc.]

CEDAX (ceftibuten capsules) and (ceftibuten for oral suspension)

Twinject [Shionogi Pharma, Inc.]

Twinject auto-injector(epinephrine injection, USP 1:1000)

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [9 Associated Companies listed on BioPortfolio]

Shionogi & Co., Ltd.

Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi’s Research ...

Shionogi Pharma, Inc.

Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi’s Research ...

Shionogi Inc.

Shionogi Inc. is a US-based company of Shionogi & Co., Ltd. Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to plac...

Shionogi-ViiV Healthcare LLC

'572 is the lead compound in Shionogi-ViiV Healthcare LLC. It is currently the only once-daily, unboosted integrase inhibitor in Phase IIb clinical development. Shionogi-ViiV Healthcare LLC is also de...

Sciele Pharma, Inc.

Shionogi & Co., Ltd. (Head Office: Osaka; President: Isao Teshirogi; hereafter “Shionogi”) today announced that its U.S.-based group company, Sciele Pharma, Inc. (hereaf...

More Information about "Shionogi & Co., Ltd." on BioPortfolio

We have published hundreds of Shionogi & Co., Ltd. news stories on BioPortfolio along with dozens of Shionogi & Co., Ltd. Clinical Trials and PubMed Articles about Shionogi & Co., Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Shionogi & Co., Ltd. Companies in our database. You can also find out about relevant Shionogi & Co., Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...


Corporate Database Quicklinks



Searches Linking to this Company Record